T4 bacteriophage nanoparticles engineered through CRISPR provide a versatile platform for rapid development of flu mucosal vaccines.
Li M, Chen C, Wang X, Guo P, Feng H, Zhang X, Zhang W, Gu C, Zhu J, Wen G, Feng Y, Xiao L, Peng G, Rao VB, Tao P.
Li M, et al. Among authors: feng y, feng h.
Antiviral Res. 2023 Sep;217:105688. doi: 10.1016/j.antiviral.2023.105688. Epub 2023 Jul 27.
Antiviral Res. 2023.
PMID: 37516153